Here are the Comparison of canagliflozin and teneligliptin on energy intake and body weight in Japanese patients with Type 2 diabetes: a subanalysis of the CANTABILE study journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.
Comparison of canagliflozin and teneligliptin brand, comparison of canagliflozin and cardiovascular, comparison of canagliflozin and teneligliptin and metformin, comparison of canagliflozin and renal outcomes, comparison of canagliflozin and teneligliptin cipla, comparison of canagliflozin and teneligliptin uses, degrees of comparison of adjectives, comparison of canagliflozin warnings, comparison of intel processors.
Comparison of canagliflozin and teneligliptin on energy intake and body weight in Japanese patients with Type 2 diabetes: a subanalysis of the CANTABILE study
Background: While the Sodium-glucose co-transporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP4) are widely used for the glycemic control in type 2 diabetes mellitus, the differences in the effects of SGLT2 inhibitors and DPP4 inhibitors on energy intake and diabetes-related indicators are unclear.
Methods: This was a subanalysis of the CANTABILE study which compared the effects of canagliflozin and teneligliptin on metabolic factors in Japanese patients with Type 2 diabetes. The changes at 24 weeks from the baseline of the diabetes-related indicators including Hemoglobin A1c (HbA1c), energy intake and body weight were compared between the canagliflozin and teneligliptin groups.
Results: Seventy-five patients in the canagliflozin group and 70 patients in the teneligliptin group were analyzed. A significant decrease in HbA1c was observed in both groups. In the teneligliptin group, although energ y intake was significantly reduced, there was no significant change in body weight. Conversely, in the canagliflozin group, although energy intake tended to increase, body weight significantly decreased.
Conclusion: Canagliflozin and teneligliptin have different effects on the dietary status of patients with Type 2 diabetes. Our result suggests that canagliflozin can manage blood glucose without weight gain, even with increased energy intake. © The Author(s) 2024.
Authors : Isogawa M.; Makino H.; Son C.; Nishimura K.; Hirata T.; Kasama S.; Miyamoto Y.; Noguchi M.; Kasahara M.; Hosoda K.
Source : BioMed Central Ltd
Article Information
| Year | 2024 |
| Type | Article |
| DOI | 10.1186/s12902-024-01690-6 |
| ISSN | 14726823 |
| Volume | 24 |
You can download the article here
If You have any problem, contact us here